Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Today’s Biggest Stock Market Losers And What To Do With Them

Page 1 of 2

There are three stocks getting beaten and bruised on high trading volume this morning, all for very different reasons. Let’s run through the news concerning each and try to determine whether they make good buys on their current weakness, or should be avoided like the plague.


Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH)

Investors with Long Positions (as of June 30): 21
Aggregate Value of Investors’ Holdings (as of June 30): $205.76 Million

Let’s start with Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH), which lands on this list for the second-straight day after shares crashed by more than 78% yesterday on the news that its IGNITE2 phase 3 clinical trial for Eravacycline failed to meet its primary endpoint. That news was met with a flurry of downgrades from analysts, ten in all, despite the fact shares had already crashed, which suggests that there is little hope for the company to turn things around, at least in the near-term. That appears to be bearing out on the markets today, as shares have fallen by another 9%, dragging down their year-to-date decline to over 78%. Thus, we don’t believe it makes for a good investment even after its severe drop. While hedge fund ownership was not overly high in Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) out of those in our database, it was the most popular stock of the three in this article. Respected investors like Steve Cohen, Ken Griffin, and Thomas Steyer are all licking their wounds today, as all had positions in the company of over 300,000 shares as of June 30.

At Insider Monkey, we track hedge funds’ moves in order to identify actionable patterns and profit from them. Our research has shown that hedge funds’ large-cap stock picks historically underperformed the S&P 500 Total Return Index by an average of seven basis points per month between 1999 and 2012. On the other hand, the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Index by an average of 95 basis points per month (read the details here). Since the official launch of our small-cap strategy in August 2012, it has performed just as predicted, returning 118% and beating the market by more than 60 percentage points. We believe the data is clear: investors will be better off by focusing on small-cap stocks utilizing hedge fund expertise (while avoiding their high fees at the same time) rather than large-cap stocks.

Meritage Homes Corp (NYSE:MTH)

Investors with Long Positions (as of June 30): 14
Aggregate Value of Investors’ Holdings (as of June 30): $380.18 Million

Next up is Meritage Homes Corp (NYSE:MTH), which has fallen by over 10% today as well, after the homebuilder was forced to lower its guidance for the full fiscal year. Meritage Homes cut its EPS forecast to a range of $3.30 to $3.75, with the mid-point of the range now falling below both the consensus estimates of $3.59, as well as the low end of the company’s previous guidance of $3.60 to $3.90. Meritage Homes Corp (NYSE:MTH), which builds both single-family homes and senior living communities, had relatively stable hedge fund activity during the second quarter, with hedge fund ownership remaining the same, though the value of their holdings did decline by over 8%, while the stock was only down by about 3% during that time. Ken Griffin was also stung by this stock, as he was the top shareholder of the company in our database as of June 30, owning over 2.75 million shares, though he did trim his holding by 19% during the quarter. Ken Fisher’s Fisher Asset Management also held a sizable position, of 1.76 million shares. Given that shares have hit a seven-month low today, we believe they make a good buying opportunity, as the revised guidance was primarily driven by production snags and not weakening demand.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!